αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Ontology highlight
ABSTRACT: This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.
DISEASE(S): Ovarian Cancer,Colorectal Cancer,Solid Tumors
PROVIDER: 2348111 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA